Pet Shield Worm Screen Spot-on Solution for Small Cats ≥ 0.5 - 2.5kg Pack of 3

Comprehensive Worm Treatment for Small Cats

Pet Shield Worm Screen 30 mg/7.5 mg Spot-on Solution provides targeted action against mixed parasitic infections in small cats weighing between 0.5 and 2.5 kg. It’s specially formulated to tackle both significant types of worms:

• Roundworms (Nematodes): Including Toxocara cati (mature adult, immature adult, L4 and L3 larvae), Toxascaris leonina (mature adult, immature adult and L4), and Ancylostoma tubaeforme (mature adult, immature adult and L4). Praziquantel is effective against these common feline parasites.
• Tapeworms (Cestodes): Such as Dipylidium caninum (mature adult and immature adult), Taenia taeniaeformis (adult), and Echinococcus multilocularis (adult). Emodepside specifically targets and eliminates these pervasive threats.

The active ingredients, Praziquantel and Emodepside, work together to paralyse and kill the parasites. Praziquantel rapidly absorbs into the parasite's surface, disrupting its metabolism. Emodepside acts at the neuromuscular junction, leading to paralysis and death of roundworms. This dual action ensures a thorough and effective worming treatment for your cat. The spot-on format makes administration simple and stress-free for both you and your pet.

As a UK regulated pharmacy, Weldricks ensures you receive trustworthy healthcare products for your pets. With our convenient delivery options, including free UK delivery over £40 and next day delivery, keeping your pet protected has never been easier.

Dosage and Treatment Schedule

The recommended minimum doses are 12 mg praziquantel / kg body weight and 3 mg emodepside / kg body weight, equivalent to 0.14 ml of the veterinary medicinal product / kg body weight.

To ensure a correct dosage, body weight should be determined as accurately as possible. Underdosing could result in ineffective use and may favour resistance development.

For the treatment of roundworms and tapeworms, a single administration per treatment is effective.

For the treatment of queens to prevent transmission of Toxocara cati (L3 larvae) through the milk to the offspring, a single administration per treatment approximately seven days prior to expected parturition (birthing) is effective.

Method of administration

Spot-on use for external application to the skin.

1. Remove the pipette from its packaging. Hold the pipette in an upright position, twist and pull the cap off.
2. Turn the cap around and place the other end of the cap back on the pipette. Push and twist the cap to break the seal, then remove the cap from the pipette.
3. Part the coat on the animal's neck at the base of the skull until the skin is visible.
4. Place the tip of the pipette onto the skin and squeeze the pipette several times to empty its contents completely and directly onto the skin in one spot. Avoid contact between the veterinary medicinal product and your fingers.

Application at the base of the skull will minimise the opportunity for the animal to lick the veterinary medicinal product off.

Contraindications

• Do not use in kittens under 8 weeks of age or weighing less than 0.5 kg.
• Do not use in cases of hypersensitivity to the active substances (praziquantel, emodepside) or to any of the excipients.

Special Warnings

• Shampooing or immersion of the animal in water directly after treatment may reduce the efficacy of the veterinary medicinal product. Treated animals therefore should not be bathed until the solution has dried.
• In the absence of the risk of co-infection with nematodes and cestodes, a narrow spectrum product should be used.
• Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.

Special Precautions for Use (Target Species)

• Apply only to the skin surface and on intact skin. Do not administer orally or parenterally.
• Avoid the treated cat or other cats in the household licking the site of application while it is wet.
• There is limited experience on the use of the veterinary medicinal product in sick and debilitated animals. Therefore, the product should not be administered to these animals.

Special Precautions for the Person Administering the Veterinary Medicinal Product

• This veterinary medicinal product can be irritating to the skin and eyes.
• Care should be taken to avoid the contents of the pipette coming into contact with the skin, eyes and mouth, including hand-to-mouth and hand-to-eye contact.
• Avoid direct contact with application area while it is wet. Keep children away from treated animals during that time.
• In case of accidental contact with the skin or eyes, wash off any skin contamination immediately with soap and water.
• Rinse the affected eyes thoroughly with clean, fresh water.
• People with known hypersensitivity to praziquantel should avoid contact with the veterinary medicinal product.
• If skin or eye symptoms persist, or in case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
• Care should be taken not to allow children to have prolonged intensive contact (for example, by sleeping) with treated cats during the first 24 hours after application of the veterinary medicinal product.
• Do not smoke, eat or drink during application.
• Wash hands after use.

Adverse Events (Cats)

Very rare (<1 animal / 10,000 animals treated, including isolated reports):

• Systemic disorders (anorexia, lethargy)
• Digestive tract disorders (salivation, vomiting, diarrhoea)¹
• Neurological disorders (e.g. ataxia, tremor)¹,²,³
• Behavioural disorders (e.g. hyperactivity, anxiety, vocalisation)
• Application site disorders (alopecia, pruritus and/or inflammation)³

¹As a result of the cat licking the application site immediately after treatment. ²Mild signs. ³Transient signs.

Other Precautions

The solvent in this veterinary medicinal product may stain certain materials including leather, fabrics, plastics and finished surfaces. Allow the application site to dry before permitting contact with such materials.

Echinococcosis represents a hazard for humans. As Echinococcosis is a notifiable disease to the WOAH, specific guidelines on the treatment and follow-up, and on the safeguard of persons, need to be obtained from the relevant competent authority.

Active Substances:

• Praziquantel: 30 mg (per 0.35 ml pipette)
• Emodepside: 7.5 mg (per 0.35 ml pipette)

Excipients:

• Butylhydroxyanisole (E320): 1.89 mg/ml
• Isopropylidene glycerol
• Lactic acid

External content warning: this link will take you to a third party website.
We cannot guarantee the Patient Information Leaflet is accurate and is for reference only.